AbbVie touts Humira defense strategy abroad as a positive sign for forthcoming U.S. battle

AbbVie's strength has long been tied to the performance of megablockbuster Humira, which is facing an existential threat as U.S. copycats creep closer. Despite a "more aggressive" than expected biosimilar challenge abroad, AbbVie believes its defense strategy—and lessons learned—will help it weather the storm.